A Randomized, Double-blind Phase 2 Study of Itacitinib in Combination With Erlotinib Versus Erlotinib Alone in Subjects With Stage IIIB/ IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Overview
- Phase
- Phase 2
- Intervention
- Itacitinib
- Conditions
- Solid Tumors and Hematologic Malignancy
- Sponsor
- Incyte Corporation
- Primary Endpoint
- Part 1: Determination of the dose of itacitinib that is safe and tolerable in combination with erlotinib as measured by the number of dose-limiting toxicities (DLTs) observed in the evaluation cohort.
- Status
- Withdrawn
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of this study is to determine if Itacitinib in combination with erlotinib is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB/Stage IV or recurrent whose tumors have EGFR activating mutations.
Detailed Description
The study consists of an open-label, safety run-in to confirm the safety of Itacitinibin combination with erlotinib in subjects with nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent whose tumors have EGFR activating mutations. Subjects in the safety run-in will receive open-label Itacitinib and erlotinib. In the second part of the study, subjects will be enrolled and randomized to receive erlotinib (open-label) and either Itacitinib or placebo in a blinded manner. The dose of Itacitinib administered will be determined from the data produced in the safety run-in phase. Treatment will consist of repeating 21-day cycles. Subjects will take erlotinib tablets daily and Itacitinib/placebo will be self-administered daily during the entire cycle.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically or cytologically confirmed diagnosis of nonsquamous NSCLC that is Stage IIIB, Stage IV, or recurrent (including Stage II).
- •Documented evidence of an activating mutation in EGFR in tumor samples (exon 19 deletions or point mutation L858R in exon 21 or point mutations at codon 719).
- •A mGPS of 1 or 2 as defined below:
- •Criteria: C-reactive protein \>10 mg/L AND albumin ≥35 g/L Score-1
- •Criteria: C-reactive protein \>10 mg L AND albumin \<35 g/L Score-2
- •Radiographically measurable or evaluable disease.
- •Life expectancy of at least 12 weeks.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to
- •Adequate renal, hepatic, and bone marrow function demonstrated by protocol-specified laboratory parameters at the screening visit.
Exclusion Criteria
- •Known presence of the T790M mutation in EGFR in tumor samples
- •Candidates for curative radiation therapy or surgery.
- •Previous systemic chemotherapy for advanced disease, including EGFR inhibitor therapy, except subjects who received 1 cycle of chemotherapy while waiting to receive EGFR results, who may enroll provided that 21 days have elapsed from end of chemotherapy to the day to the baseline radiographic measurement prior to Cycle 1 Day
- •Distinct or suspected, or history of, pulmonary fibrosis or ILD.
- •Current or previous other malignancy within 2 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive indolent or Stage I malignancy without sponsor approval.
Arms & Interventions
Itacitinib plus erlotinib
Intervention: Itacitinib
Itacitinib plus erlotinib
Intervention: erlotinib
Placebo plus erlotinib
Intervention: erlotinib
Placebo plus erlotinib
Intervention: placebo
Outcomes
Primary Outcomes
Part 1: Determination of the dose of itacitinib that is safe and tolerable in combination with erlotinib as measured by the number of dose-limiting toxicities (DLTs) observed in the evaluation cohort.
Time Frame: Baseline through Day 21
Subjects will take erlotinib daily and begin dosing with itacitinib once daily (QD) on Cycle 1, Day 1. The safety and tolerability of the regimen will be assessed during the first 21 days of therapy
Part 2: Overall Survival (OS)
Time Frame: Randomization until death. Approximately 31 months.
Part 2: Progression-free survival (PFS)
Time Frame: Randomization to disease progression, or death due to any cause if sooner. Approximately 23 months.
PFS is defined as the time from randomization until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause if sooner.
Secondary Outcomes
- Part 2: Objective Response(Baseline through end of study. Approximately 31 months.)
- Part 2: Duration of Response(Baseline through end of study. Approximately 31 months.)
- Part 2: Safety and tolerability of the treatment regimens assessed by a summary of adverse events and clinical laboratory assessments.(Baseline through approximately 30 days post treatment discontinuation. Assessed after approximately 31 months.)